ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

July 1, 2006

MENLO PARK, Calif—Chem-Genex Pharmaceuticals has launched a multinational phase II/III trial of Ceflatonin (homoharringtonine, HHT) in chronic myeloid leukemia patients who have the T315I bcr-abl point mutation, which makes them resistant to tyrosine kinase inhibitors (TKIs) such as imatinib(Drug information on imatinib) (Gleevec). In April, FDA granted Ceflatonin orphan drug status for the treatment of CML.

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

FROM PHYSICIANS PRACTICE

Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.

Improving Care Coordination in Your Practice
Susanne Madden, June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.

Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler, June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.

Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate, June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.

iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.

ChemGenex Launches Trial of Ceflatonin in TKI-Resistant CML

Join the Conversation